133 related articles for article (PubMed ID: 20484556)
1. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion.
Kodama K; Fujisaki H; Kubota A; Kato H; Hirota K; Kuramochi H; Murota M; Tabata Y; Ueda M; Harada H; Kawahara T; Shinoda M; Watanabe N; Iida D; Terauchi H; Yasui S; Miyazawa S; Nagakawa J
J Pharmacol Exp Ther; 2010 Aug; 334(2):395-401. PubMed ID: 20484556
[TBL] [Abstract][Full Text] [Related]
2. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
3. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
5. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
6. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Mori H; Tonai-Kachi H; Ochi Y; Taniguchi Y; Ohshiro H; Takahashi N; Aihara T; Hirao A; Kato T; Sakakibara M; Kurebayashi Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):671-9. PubMed ID: 18981288
[TBL] [Abstract][Full Text] [Related]
7. Soraprazan: setting new standards in inhibition of gastric acid secretion.
Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
Wallmark B; Lorentzon P; Larsson H
Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
[TBL] [Abstract][Full Text] [Related]
9. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
Fryklund J; Wallmark B
J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
[TBL] [Abstract][Full Text] [Related]
10. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
11. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
[TBL] [Abstract][Full Text] [Related]
12. KFP-H008 blocks gastric acid secretion through inhibiting H
Li CY; Su M; Yan YY; Zhou L; Ao LY; Fang WR; Li YM
Eur J Pharmacol; 2017 Sep; 810():112-119. PubMed ID: 28629736
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews.
Schultz C; Bossolani MP; Torres LM; Lima-Landman MT; Lapa AJ; Souccar C
J Ethnopharmacol; 2007 Apr; 111(1):1-7. PubMed ID: 17166678
[TBL] [Abstract][Full Text] [Related]
14. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
[TBL] [Abstract][Full Text] [Related]
15. Novel 1H-pyrrolo[2,3-c]pyridines as acid pump antagonists (APAs).
Yoon YA; Kim DH; Lee BM; Kim TK; Cha MH; Sim JY; Kim JG
Bioorg Med Chem Lett; 2010 Sep; 20(17):5237-40. PubMed ID: 20656486
[TBL] [Abstract][Full Text] [Related]
16. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
17. Review article: is stringent control of gastric pH useful and practical in GERD?
Kahrilas PJ
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
[TBL] [Abstract][Full Text] [Related]
18. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.
Smolka AJ; Goldenring JR; Gupta S; Hammond CE
BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114
[TBL] [Abstract][Full Text] [Related]
20. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
